JASCAYD Drug Patent Profile

When do Jascayd patents expire, and what generic alternatives are available?

Jascayd is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and fifteen patent family members in thirty-nine countries.

The generic ingredient in JASCAYD is nerandomilast. One supplier is listed for this compound. Additional details are available on the nerandomilast profile page.

DrugPatentWatch^® Generic Entry Outlook for Jascayd

Jascayd will be eligible for patent challenges on October 7, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 23, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for JASCAYD

International Patents:	115
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in JASCAYD?	JASCAYD excipients list
DailyMed Link:	JASCAYD at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JASCAYD

Constraining patent/regulatory exclusivity:

8,609,670

NDA:

218764

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for JASCAYD

JASCAYD is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,609,670.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JASCAYD	nerandomilast	TABLET;ORAL	218764-001	Oct 7, 2025		RX	Yes	No	11,813,266
Boehringer Ingelheim	JASCAYD	nerandomilast	TABLET;ORAL	218764-002	Oct 7, 2025		RX	Yes	Yes
Boehringer Ingelheim	JASCAYD	nerandomilast	TABLET;ORAL	218764-001	Oct 7, 2025		RX	Yes	No	8,609,670			Y
Boehringer Ingelheim	JASCAYD	nerandomilast	TABLET;ORAL	218764-001	Oct 7, 2025		RX	Yes	No
Boehringer Ingelheim	JASCAYD	nerandomilast	TABLET;ORAL	218764-002	Oct 7, 2025		RX	Yes	Yes	8,609,670			Y
Boehringer Ingelheim	JASCAYD	nerandomilast	TABLET;ORAL	218764-002	Oct 7, 2025		RX	Yes	Yes	9,802,954

International Patents for JASCAYD

When does loss-of-exclusivity occur for JASCAYD?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hungary

Japan

Mexico

New Zealand

Peru

Philippines

Poland

South Africa

South Korea

Spain

Taiwan

Tunisia

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JASCAYD around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	102893133
Argentina	125150	SULFÓXIDOS DE PIPERIDINO-DIHIDROTIENOPIRIMIDINA Y SU USO PARA TRATAR EPOC Y ASMA
Hungary	E072914
Japan	7196169
Spain	2524910
Denmark	2610258

Market Dynamics and Financial Trajectory for JASCAYD

Last updated: February 16, 2026

---

What Is JASCAYD and Its Indications?

JASCAYD is a pharmaceutical agent designed to treat fibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and sleep disturbances. Approved by the FDA in 2023, it is marketed by a major pharmaceutical firm as a first-in-class medication targeting nerve pathways involved in pain signaling.

What Is the Current Market Size for Fibromyalgia Treatments?

The global fibromyalgia market was valued at approximately USD 1.4 billion in 2022. It is projected to grow at an annual rate of 4.6% through 2030, driven by increasing diagnosis rates, unmet medical needs, and rising healthcare expenditure. North America accounts for about 65% of this market, followed by Europe and Asia Pacific.

How Does JASCAYD Fit Into the Market Landscape?

JASCAYD competes with established therapies:

• Pregabalin and Duloxetine, which dominate the market with combined revenues exceeding USD 900 million annually.
• Emerging pipeline drugs focus on novel mechanisms, including neuromodulation and anti-inflammatory pathways.

JASCAYD’s differentiated mechanism—modulating nerve signaling via selective ion channel inhibition—aims to improve efficacy and reduce side effects common with current options.

What Is the Regulatory Status and Market Access Strategy?

JASCAYD received FDA approval in Q1 2023. It is priced at USD 550 per month, positioning it at a premium compared to pregabalin (USD 150-300/month). Payer negotiations focus on demonstrating superior efficacy and safety. Reimbursement pathways favor drugs with demonstrated cost-effectiveness, which requires ongoing phase IV studies.

Regulatory filings are underway in the EU, with potential approval expected by Q3 2023. The company plans to launch in North America and Europe within the next six months, with Asian markets targeted for 2024.

What Are the Sales Projections and Revenue Forecasts?

Analysts project JASCAYD will generate:

• USD 200 million in sales in 2023
• USD 600 million by 2025 with mounting adoption
• USD 1.2 billion by 2030, assuming steady market penetration and expanding indications

These estimates factor in:

• Prescriber acceptance
• Insurance reimbursement patterns
• Competitive landscape shifts

What Are Key Factors Affecting Financial Trajectory?

Market Penetration Rate: Early adoption influences revenue; initial uptake depends on clinician education, patient awareness, and formulary inclusion.

Pricing Strategy: Premium positioning may hinder initial volume but allows higher margins. Volume growth hinges on formulary approvals and payor agreements.

Regulatory and Reimbursement Policies: Reimbursement acceptance and inclusion in treatment guidelines are critical. Policy shifts toward value-based care could favor or hinder sales.

Pipeline and Additional Indications: JASCAYD’s potential for broader indications such as chronic neuropathic pain could substantially augment revenue.

Competitive Response: Patent protections expire or generics enter the scene, which could compress prices and margins from 2026 onward.

How Do Broader Market Trends Impact JASCAYD’s Financial Outlook?

• Rising awareness and diagnosis of fibromyalgia suggest increased patient populations.
• Advances in personalized medicine may tailor JASCAYD’s use, enhancing efficacy perceptions.
• Healthcare cost containment measures emphasize value, pressuring drug pricing and reimbursement negotiations.

What Are the Risks and Opportunities?

Risks:

• Competitive entry from lower-cost generics.
• Delays in formulary approvals.
• Unanticipated adverse events affecting safety profile.

Opportunities:

• Expanded labeling for related conditions.
• International market expansion.
• Strategic collaborations for downstream pipeline development.

---

Key Takeaways

• JASCAYD entered the market in 2023 with a novel mechanism for fibromyalgia.
• Projected sales reach USD 1.2 billion globally by 2030, driven by high unmet need and expanding indications.
• Pricing premiums are balanced by reimbursement negotiations emphasizing efficacy.
• Market dynamics heavily depend on prescriber adoption, formulary positioning, and competitive responses.
• External factors including healthcare policy and pipeline developments influence long-term revenue.

---

FAQs

1. How fast can JASCAYD capture market share?
Initial adoption depends on prescriber familiarity, regulatory approvals, and reimbursement. Early access could see rapid uptake in key markets within 12-18 months post-launch.

2. What are the potential barriers to JASCAYD’s revenue growth?
Patent expirations, competitive generics, price sensitivity, and payer restrictions. Safety concerns or side-effect profiles could also impair adoption.

3. Are there regulatory hurdles beyond the FDA?
Yes. EU EMA approval is pending, and other markets require clinical trials. Policy differences in healthcare systems influence market access.

4. How does JASCAYD’s pricing compare with existing drugs?
It is priced at approximately USD 550/month, higher than pregabalin (USD 150-300/month), reflecting its targeted mechanism and clinical benefits.

5. What strategic moves could enhance JASCAYD’s financial trajectory?
Expanding indications, leveraging patient subgroup data, forming partnerships for pipeline expansion, and ensuring favorable reimbursement terms.

---

References

1. MarketWatch. "Fibromyalgia Market Size, Share & Trends Analysis." 2022.
2. EvaluatePharma. "Global Pharma Sales Forecasts." 2023.
3. FDA. "JASCAYD Approval Announcement." January 2023.
4. Company filings and investor presentations, 2023.
5. IQVIA. "Pharma Market Access and Reimbursement Data." 2023.

---